Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
<h4>Background</h4>Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymph...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8a6f737eb02e4bb2b26604dc216cc95b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8a6f737eb02e4bb2b26604dc216cc95b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8a6f737eb02e4bb2b26604dc216cc95b2021-11-25T05:37:01ZStatins impair antitumor effects of rituximab by inducing conformational changes of CD20.1549-12771549-167610.1371/journal.pmed.0050064https://doaj.org/article/8a6f737eb02e4bb2b26604dc216cc95b2008-03-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18366248/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymphoma effects. The objective of this study was to evaluate the influence of statins on rituximab-induced killing of B cell lymphomas.<h4>Methods and findings</h4>Complement-dependent cytotoxicity (CDC) was assessed by MTT and Alamar blue assays as well as trypan blue staining, and antibody-dependent cellular cytotoxicity (ADCC) was assessed by a 51Cr release assay. Statins were found to significantly decrease rituximab-mediated CDC and ADCC of B cell lymphoma cells. Incubation of B cell lymphoma cells with statins decreased CD20 immunostaining in flow cytometry studies but did not affect total cellular levels of CD20 as measured with RT-PCR and Western blotting. Similar effects are exerted by other cholesterol-depleting agents (methyl-beta-cyclodextrin and berberine), but not filipin III, indicating that the presence of plasma membrane cholesterol and not lipid rafts is required for rituximab-mediated CDC. Immunofluorescence microscopy using double staining with monoclonal antibodies (mAbs) directed against a conformational epitope and a linear cytoplasmic epitope revealed that CD20 is present in the plasma membrane in comparable amounts in control and statin-treated cells. Atomic force microscopy and limited proteolysis indicated that statins, through cholesterol depletion, induce conformational changes in CD20 that result in impaired binding of anti-CD20 mAb. An in vivo reduction of cholesterol induced by short-term treatment of five patients with hypercholesterolemia with atorvastatin resulted in reduced anti-CD20 binding to freshly isolated B cells.<h4>Conclusions</h4>Statins were shown to interfere with both detection of CD20 and antilymphoma activity of rituximab. These studies have significant clinical implications, as impaired binding of mAbs to conformational epitopes of CD20 elicited by statins could delay diagnosis, postpone effective treatment, or impair anti-lymphoma activity of rituximab.Magdalena WiniarskaJacek BilEwa WilczekGrzegorz M WilczynskiMalgorzata LekkaPatrick J EngelbertsWendy J M MackusElzbieta GorskaLukasz BojarskiTomasz StoklosaDominika NowisZuzanna KurzajMarcin MakowskiEliza GlodkowskaTadeusz IssatPiotr MrowkaWitold LasekAnna Dabrowska-IwanickaGrzegorz W BasakMaria WasikKrzysztof WarzochaMaciej SinskiZbigniew GaciongMarek JakobisiakPaul W H I ParrenJakub GolabPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 5, Iss 3, p e64 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Magdalena Winiarska Jacek Bil Ewa Wilczek Grzegorz M Wilczynski Malgorzata Lekka Patrick J Engelberts Wendy J M Mackus Elzbieta Gorska Lukasz Bojarski Tomasz Stoklosa Dominika Nowis Zuzanna Kurzaj Marcin Makowski Eliza Glodkowska Tadeusz Issat Piotr Mrowka Witold Lasek Anna Dabrowska-Iwanicka Grzegorz W Basak Maria Wasik Krzysztof Warzocha Maciej Sinski Zbigniew Gaciong Marek Jakobisiak Paul W H I Parren Jakub Golab Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. |
| description |
<h4>Background</h4>Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymphoma effects. The objective of this study was to evaluate the influence of statins on rituximab-induced killing of B cell lymphomas.<h4>Methods and findings</h4>Complement-dependent cytotoxicity (CDC) was assessed by MTT and Alamar blue assays as well as trypan blue staining, and antibody-dependent cellular cytotoxicity (ADCC) was assessed by a 51Cr release assay. Statins were found to significantly decrease rituximab-mediated CDC and ADCC of B cell lymphoma cells. Incubation of B cell lymphoma cells with statins decreased CD20 immunostaining in flow cytometry studies but did not affect total cellular levels of CD20 as measured with RT-PCR and Western blotting. Similar effects are exerted by other cholesterol-depleting agents (methyl-beta-cyclodextrin and berberine), but not filipin III, indicating that the presence of plasma membrane cholesterol and not lipid rafts is required for rituximab-mediated CDC. Immunofluorescence microscopy using double staining with monoclonal antibodies (mAbs) directed against a conformational epitope and a linear cytoplasmic epitope revealed that CD20 is present in the plasma membrane in comparable amounts in control and statin-treated cells. Atomic force microscopy and limited proteolysis indicated that statins, through cholesterol depletion, induce conformational changes in CD20 that result in impaired binding of anti-CD20 mAb. An in vivo reduction of cholesterol induced by short-term treatment of five patients with hypercholesterolemia with atorvastatin resulted in reduced anti-CD20 binding to freshly isolated B cells.<h4>Conclusions</h4>Statins were shown to interfere with both detection of CD20 and antilymphoma activity of rituximab. These studies have significant clinical implications, as impaired binding of mAbs to conformational epitopes of CD20 elicited by statins could delay diagnosis, postpone effective treatment, or impair anti-lymphoma activity of rituximab. |
| format |
article |
| author |
Magdalena Winiarska Jacek Bil Ewa Wilczek Grzegorz M Wilczynski Malgorzata Lekka Patrick J Engelberts Wendy J M Mackus Elzbieta Gorska Lukasz Bojarski Tomasz Stoklosa Dominika Nowis Zuzanna Kurzaj Marcin Makowski Eliza Glodkowska Tadeusz Issat Piotr Mrowka Witold Lasek Anna Dabrowska-Iwanicka Grzegorz W Basak Maria Wasik Krzysztof Warzocha Maciej Sinski Zbigniew Gaciong Marek Jakobisiak Paul W H I Parren Jakub Golab |
| author_facet |
Magdalena Winiarska Jacek Bil Ewa Wilczek Grzegorz M Wilczynski Malgorzata Lekka Patrick J Engelberts Wendy J M Mackus Elzbieta Gorska Lukasz Bojarski Tomasz Stoklosa Dominika Nowis Zuzanna Kurzaj Marcin Makowski Eliza Glodkowska Tadeusz Issat Piotr Mrowka Witold Lasek Anna Dabrowska-Iwanicka Grzegorz W Basak Maria Wasik Krzysztof Warzocha Maciej Sinski Zbigniew Gaciong Marek Jakobisiak Paul W H I Parren Jakub Golab |
| author_sort |
Magdalena Winiarska |
| title |
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. |
| title_short |
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. |
| title_full |
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. |
| title_fullStr |
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. |
| title_full_unstemmed |
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. |
| title_sort |
statins impair antitumor effects of rituximab by inducing conformational changes of cd20. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2008 |
| url |
https://doaj.org/article/8a6f737eb02e4bb2b26604dc216cc95b |
| work_keys_str_mv |
AT magdalenawiniarska statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT jacekbil statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT ewawilczek statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT grzegorzmwilczynski statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT malgorzatalekka statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT patrickjengelberts statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT wendyjmmackus statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT elzbietagorska statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT lukaszbojarski statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT tomaszstoklosa statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT dominikanowis statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT zuzannakurzaj statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT marcinmakowski statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT elizaglodkowska statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT tadeuszissat statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT piotrmrowka statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT witoldlasek statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT annadabrowskaiwanicka statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT grzegorzwbasak statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT mariawasik statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT krzysztofwarzocha statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT maciejsinski statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT zbigniewgaciong statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT marekjakobisiak statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT paulwhiparren statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 AT jakubgolab statinsimpairantitumoreffectsofrituximabbyinducingconformationalchangesofcd20 |
| _version_ |
1718414589154033664 |